{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:45:33Z","timestamp":1794372333947,"version":"4.9.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lungcan.2024.107999","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T02:16:23Z","timestamp":1730254583000},"page":"107999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9379-641X","authenticated-orcid":false,"given":"Megan","family":"Vince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Mahrukh Hussnain","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Pellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Verbosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2642-2411","authenticated-orcid":false,"given":"Dan","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.lungcan.2024.107999_b0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/OTT.S272552","article-title":"Extensive-stage small-cell lung cancer: current landscape and future prospects","volume":"2","author":"Saida","year":"2023","journal-title":"Onco Targets Ther."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107999_b0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107999_b0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107999_b0020","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3390\/curroncol30070465","article-title":"Canadian consensus recommendations on the management of extensive-stage small-cell lung cancer","volume":"30","author":"Melosky","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2024.107999_b0025","unstructured":"National Comprehensive Cancer Network. (2023). Non-Small Cell Lung Cancer (version 3.2023)."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107999_b0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2024.107999_b0035","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2024.107999_b0040","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107999_b0045","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.21037\/jtd-23-588","article-title":"Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study","volume":"15","author":"Zou","year":"2023","journal-title":"J. Thorac. Dis."},{"issue":"15","key":"10.1016\/j.lungcan.2024.107999_b0050","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025180","article-title":"Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive stage small cell lung cancer. A systemic review and network meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107999_b0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","article-title":"Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab","volume":"9","author":"Tan","year":"2018","journal-title":"Protein Cell."},{"key":"10.1016\/j.lungcan.2024.107999_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients. A large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107999_b0065","first-page":"36","article-title":"Hyponatremia in small cell lung cancer is associated with a poorer prognosis","volume":"5","author":"Wang","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107999_b0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1159\/000532087","article-title":"The Glasgow prognostic score predicts survival outcomes in patients with extensive-stage small cell lung cancer","volume":"101","author":"Igawa","year":"2023","journal-title":"Oncology"},{"issue":"15","key":"10.1016\/j.lungcan.2024.107999_b0075","doi-asserted-by":"crossref","first-page":"20077","DOI":"10.1200\/JCO.2019.37.15_suppl.e20077","article-title":"Exploring sex differences in small cell lung cancer: Is this a hormonal issue?","volume":"37","author":"Duma","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107999_b0080","first-page":"232","article-title":"The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit","volume":"21","author":"Wheatley-Price","year":"2010","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T21:22:36Z","timestamp":1733260956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":16,"alternative-id":["S0169500224005336"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107999","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107999"}}